Truist Securities Downgrades PTC Therapeutics to Hold, Announces $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has downgraded PTC Therapeutics (NASDAQ:PTCT) from Buy to Hold and set a price target of $25.
October 06, 2023 | 9:10 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PTC Therapeutics has been downgraded from Buy to Hold by Truist Securities, with a new price target of $25.
The downgrade from Buy to Hold by Truist Securities indicates a less optimistic outlook for PTC Therapeutics. The new price target of $25 may also suggest that the analyst believes the stock is currently overvalued. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100